Rectal tumours disappear in experimental cancer drug trial, but too ...
ABC News - 10 Jun 2022An experimental drug cleared tumours from a dozen people with a specific type of rectal cancer, but experts say there's loads more work to be done.
Dostarlimab
An experimental drug cleared tumours from a dozen people with a specific type of rectal cancer, but experts say there's loads more work to be done.
STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma
BMC Cancer - 01 Jul 2025STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma ...
Dostarlimab: Review on success story and clinical trials
ScienceDirect - 08 Jan 2025Dostarlimab: Review on success story and clinical trials ...
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Targeted Oncology - 16 Dec 2024FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer ...
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer
CancerNetwork - 20 Jan 2025Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer ...
A New Immune Treatment May Work Against Several Cancer Types
Time Magazine - 28 Apr 2025A New Immune Treatment May Work Against Several Cancer Types ...
Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors
OncLive - 28 Apr 2025Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors ...
Diagram depicting the action mechanism of dostarlimab against cancer...
researchgate.net - 20 May 2025Diagram depicting the action mechanism of dostarlimab against cancer... ...
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
Nature - 27 Feb 2025CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours ...
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
ScienceDirect - 21 Jan 2025Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) ...
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer ...
Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
CancerNetwork - 20 Mar 2025Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial ...
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer ...
Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer
CancerNetwork - 16 Dec 2024Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer ...
Dostarlimab Plus Chemo With Maintenance Niraparib Generates Modest PFS Boost in Advanced Ovarian Cancer
OncLive - 02 Jun 2025Dostarlimab Plus Chemo With Maintenance Niraparib Generates Modest PFS Boost in Advanced Ovarian Cancer ...
Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors
CancerNetwork - 29 Apr 2025Organ Preservation Noted With Neoadjuvant Dostarlimab in dMMR Tumors ...
Dostarlimab Yields High cCR Rates and Organ Preservation in Early-Stage dMMR Tumors
OncLive - 09 May 2025Dostarlimab Yields High cCR Rates and Organ Preservation in Early-Stage dMMR Tumors ...
Dostarlimab/Chemo, Maintenance Niraparib Show Modest Improvements in Ovarian Cancer
CancerNetwork - 02 Jun 2025Dostarlimab/Chemo, Maintenance Niraparib Show Modest Improvements in Ovarian Cancer ...
Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Endometrial Cancer
OncLive - 18 Mar 2025Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Endometrial Cancer ...
Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer
OncLive - 20 Dec 2024Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer ...